Pioneering adhesive surgical film manufacturer Tissuemed Ltd (Leeds, UK) has announced that it has entered into an exclusive distribution agreement with Medtronic – one of the largest medical technology companies in the world.
The agreement, which starts from September, gives Medtronic exclusive distribution rights to sell Tissuemed’s neuro and spinal products – a range of ultra thin adhesive films, which adhere to the body’s internal tissues to prevent the leakage of Cerebrospinal Fluid encountered in surgery – in specific countries around the world including most of Europe as well as other major markets.
The product will be marketed as ‘Obex Neurofilm’ and offers global neurosurgeons a pioneering breakthrough solution to prevent cerebrospinal fluid leaks after surgery; reducing the need for extended hospital stay and in worst cases, additional surgery.
Speaking about the partnership Tissuemed’s CEO Nick Woods, said: “It is a superb opportunity for us to have our surgical films marketed by one of the world’s biggest and most respected players in the field. It is also a major endorsement for our pioneering technology, which is already revolutionising surgical procedures worldwide.”
“Going forward working with Medtronic means they can address what is currently a poorly met surgical need with a technology-based solution and we can focus our activities on accelerating the development of new iterations in new surgical disciplines.”
Mark Fletcher, Medtronic President of Medtronic’s Ear Nose and Throat and Neurotechnologies Division, said: “We have been searching for a sealant to fit with our neuro technology and spine business for quite a while and so were delighted to come across Tissuemed. They are a great company with amazing technology.
“What I like about the technology is that it works like a bandage. You just apply pressure for 30 seconds and it works, it’s that simple. We have already shown it to a number of surgeons in the US and their feedback was excellent. In fact many remarked that it was the best product they have seen us come forward with so we are very encouraged and expect it to do incredibly well in the future.”
Over the last few weeks Medtronic’s team of European managers have been at Tissuemed’s head office in Leeds to take part in product training workshops. They will now start selling the product across Europe, with the view to selling it in the US once FDA approval has been granted.